Evidence map›Paper›PMID 37589434›Full record

ArticlePathology international2023

The risk of weekend biopsy: Impact of specimen source and fixation status on HER2 assessment in the treatment of advanced gastric cancer (The HER_WEEKEND study).

Michio Nakamura, Ayako Watanabe, Aki Yoshizawa, Sari Iwasaki, Asako Nomura, Mariko Matsumura, Taichi Murai, Kazufumi Itaya, Yuta Koike, Takaaki Izumi and 11 more

Abstract read
In one paragraph

Article in Pathology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Michio NakamuraDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0002-1509-9811
Ayako WatanabeDepartment of Clinical Laboratories, Sapporo City General Hospital, Sapporo, Japan.
Aki YoshizawaDepartment of Clinical Laboratories, Sapporo City General Hospital, Sapporo, Japan.
Sari IwasakiDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Asako NomuraDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Mariko MatsumuraDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Taichi MuraiDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Kazufumi ItayaDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Yuta KoikeDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Takaaki IzumiDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Ayana EndoDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Shin KatoDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Yuji OnoDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Takahiro OhshimaDepartment of Surgery, Sapporo City General Hospital, Sapporo, Japan.
Nanase OkazakiDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Shimpei NakagawaDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Yasushi IshiiDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Yuichiro FukasawaDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Takahiro TsujiDepartment of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Shuji NishikawaDepartment of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate evaluation of human epidermal growth factor receptor type 2 (HER2) expression is crucial for determining chemotherapy regimens in gastric cancer. However, formalin fixation status has been identified as an important factor affecting HER2 assessment reliability. This retrospective cohort study aimed to investigate the correlation between sample collection day (weekday vs. weekend) and source (biopsy vs. surgical specimens) in assessing HER2 expression in patients with unresectable advanced/recurrent gastric cancer. Data were collected from gastric cancer patients who received chemotherapy at a single public hospital in Japan from 2008 to 2021. The analysis included 177 patients (109 men, 68 women) with a median age of 68.0 (21-88) years, and the primary outcome was the HER2 positivity rate. The overall HER2 positivity rate was 18.1%, with higher rates on weekdays (20.0%) compared to weekends (12.8%). Biopsies had higher positivity rates on weekdays (23.9%) but lower rates on weekends (11.1%) than surgical specimens. Significant differences were observed in formalin fixation times between weekdays and weekends for both biopsies and surgical samples. The study findings suggest that longer formalin fixation times on weekends may lead to underestimating HER2 expression, particularly in biopsies. Therefore, it is crucial to be cautious of excessive formalin fixation when collecting samples, especially during weekend biopsies.

Indexed as

Stomach NeoplasmsAgedAged, 80 and overBiomarkers, TumorBiopsyErb-b2 Receptor Tyrosine KinasesFemaleFormaldehydeHumansMaleReproducibility of ResultsRetrospective StudiesBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFormaldehydebiopsyformalin fixationgastric cancerHER2immunohistochemistry

Identifiers

PMID37589434
PMCPMC11551806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.